TLS Advisors LLC Trims Stake in Xenon Pharmaceuticals Inc. $XENE

TLS Advisors LLC cut its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 42.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 18,858 shares of the biopharmaceutical company’s stock after selling 14,098 shares during the period. Xenon Pharmaceuticals accounts for about 1.5% of TLS Advisors LLC’s holdings, making the stock its 11th biggest position. TLS Advisors LLC’s holdings in Xenon Pharmaceuticals were worth $845,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of XENE. Danske Bank A S acquired a new position in Xenon Pharmaceuticals in the 3rd quarter valued at $32,000. Blue Trust Inc. raised its holdings in Xenon Pharmaceuticals by 2,560.7% in the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 717 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new position in Xenon Pharmaceuticals in the 3rd quarter valued at $39,000. Osaic Holdings Inc. raised its holdings in Xenon Pharmaceuticals by 541.4% in the 2nd quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 1,034 shares during the last quarter. Finally, State of Wyoming increased its holdings in shares of Xenon Pharmaceuticals by 112.8% during the 3rd quarter. State of Wyoming now owns 1,151 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 610 shares during the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Xenon Pharmaceuticals

In related news, CEO Ian Mortimer sold 7,308 shares of the stock in a transaction on Friday, March 13th. The stock was sold at an average price of $55.23, for a total value of $403,620.84. Following the completion of the sale, the chief executive officer directly owned 19,923 shares in the company, valued at approximately $1,100,347.29. This represents a 26.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Christopher John Kenney sold 1,410 shares of the stock in a transaction on Friday, March 13th. The shares were sold at an average price of $55.23, for a total value of $77,874.30. Following the completion of the sale, the insider owned 7,069 shares of the company’s stock, valued at approximately $390,420.87. This represents a 16.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 296,707 shares of company stock worth $17,845,365. Corporate insiders own 4.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Robert W. Baird upped their price objective on Xenon Pharmaceuticals from $63.00 to $97.00 and gave the stock an “outperform” rating in a report on Monday, March 9th. Bank of America restated a “buy” rating on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Wolfe Research assumed coverage on Xenon Pharmaceuticals in a report on Monday, February 23rd. They set an “outperform” rating and a $60.00 price objective for the company. Guggenheim restated a “buy” rating and set a $90.00 price objective on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Finally, JPMorgan Chase & Co. upped their price objective on Xenon Pharmaceuticals from $77.00 to $80.00 and gave the stock an “overweight” rating in a report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Xenon Pharmaceuticals presently has an average rating of “Buy” and an average target price of $75.69.

Xenon Pharmaceuticals Trading Down 1.4%

Shares of NASDAQ XENE opened at $55.00 on Wednesday. Xenon Pharmaceuticals Inc. has a 12-month low of $28.19 and a 12-month high of $63.95. The company has a market cap of $5.32 billion, a P/E ratio of -11.70 and a beta of 0.65. The stock has a fifty day moving average price of $55.33 and a 200 day moving average price of $46.89.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.17). During the same period last year, the company earned ($0.83) earnings per share. On average, sell-side analysts forecast that Xenon Pharmaceuticals Inc. will post -4.87 EPS for the current fiscal year.

More Xenon Pharmaceuticals News

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: JPMorgan Chase & Co. raised its price target on Xenon Pharmaceuticals to $80 from $77 and reiterated an Overweight rating, implying significant upside from the current share price. Benzinga article
• Positive Sentiment: HC Wainwright lifted earnings estimates across multiple periods, including FY2026, FY2027, FY2028, FY2029, and FY2030, while maintaining a Buy rating and a $74 price target, signaling improved long-term expectations for Xenon.
• Positive Sentiment: Recent headlines referenced positive X-TOLE2 phase 3 data and an extended cash runway, which may support the company’s valuation and reduce financing concerns. Yahoo Finance article
• Neutral Sentiment: HC Wainwright also adjusted near-term quarterly EPS estimates higher for Q2, Q3, and Q4 2026, though Xenon is still expected to post losses, so the impact is more about improving outlook than near-term profitability.
• Neutral Sentiment: Short interest data showed no meaningful update, with reported short interest at zero shares, offering little signal for trading sentiment.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical?stage biopharmaceutical company dedicated to discovering and developing novel, small?molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion?channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion?channel biology and structure?based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.